On September 6, 2022 Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, reported that members of management will present at two upcoming investor conferences. Details are as follows (Press release, Mersana Therapeutics, SEP 6, 2022, View Source [SID1234619023]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Morgan Stanley 20th Annual Global Healthcare Conference
Format: Fireside Chat
Date/Time: Monday, September 12, 2022, at 4:15 p.m. Eastern Time

Baird 2022 Global Healthcare Conference
Format: Fireside Chat
Date/Time: Tuesday, September 13, 2022, at 2:00 p.m. Eastern Time
A live webcast of the fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference will be available on the Investors & Media section of Mersana’s website at www.mersana.com. An archived replay will be available for approximately 90 days following the event.

On September 6, 2022 Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, reported the publication of abstracts reporting clinical data and trial design for tumor infiltrating lymphocyte (TIL) cell therapies at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2022 in Paris, France, September 9 – 13, 2022 (Press release, Iovance Biotherapeutics, SEP 6, 2022, View Source [SID1234619022]). The details of the abstracts, which are available on Iovance.com, are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abstract #844P: Efficacy and safety of lifileucel, an investigational autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma previously treated with anti-LAG3 antibody
Presentation Type: Poster
Authors: James Larkin, et al.
Date: Saturday, September 10, 2022, 9 a.m. CET to 5 p.m. CET, Hall 4

Abstract #883TiP: A phase 1/2 open-label study (IOV-GM1-201) of TALEN-mediated PD-1 inactivated autologous tumor-infiltrating lymphocytes (TIL; IOV-4001) in patients with advanced melanoma and NSCLC
Presentation Type: Trial in Progress (TiP) Poster
Authors: Jason Chesney, et al.
Date: Saturday, September 10, 2022, 9 a.m. CET to 5 p.m. CET, Hall 4

On September 6, 2022 Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, reported that Chief Executive Officer Piers Ingram, Ph.D., and Chief Financial Officer Josh House will participate in one-on-one investor meetings at Morgan Stanley’s 20th Annual Global Healthcare Conference (September 12-14, 2022), held at the Sheraton New York Hotel in New York City (Press release, Hummingbird Bioscience, SEP 6, 2022, View Source [SID1234619021]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 6, 2022 Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, reported that Mel Sorensen, M.D., President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022 at 4:30 p.m. E.T (Press release, Galera Therapeutics, SEP 6, 2022, View Source [SID1234619020]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be accessible from the Investors page of Galera’s website, investors.galeratx.com. An archived version of the webcast will be available in the Events & Presentations section of the Investors page of Galera’s website for 30 days following the event.

On September 6, 2022 G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, reported that the Company will host a virtual R&D Day, "Innovations in Oncology: The Science of Trilaciclib", on Thursday, September 15, 2022, from 9:00 a.m. to 11:00 a.m. ET (Press release, G1 Therapeutics, SEP 6, 2022, View Source [SID1234619019]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

G1 will review the development and expansion strategy for trilaciclib, its innovative investigational therapy to improve the lives and outcomes of people living with cancer. The Company will also present new preclinical data supporting potential of trilaciclib to work synergistically with other anti-cancer therapies. Trilaciclib is currently in clinical trials assessing its myeloprotective and anti-tumor immunomodulatory effects in a range of tumor types and in combination with a variety of treatments, including ADCs and checkpoint inhibitors.

Additionally, the program will feature insights from leading clinicians on the differentiated and broadly applicable immune-based mechanism of action of trilaciclib; the importance of transient CDK4/6 inhibition; and the urgent need to improve treatment options for patients with colorectal cancer:

Shom Goel, B Med Sci, MBBS, FRACP, PhD, Peter MacCallum Cancer Centre, The University of Melbourne
Richard Goldberg, MD, Professor Emeritus and former Director, West Virginia University Cancer Institute (WVUCI)
A webcast of the event can be accessed on the Events & Presentations page of www.g1therapeutics.com. The webcast will be archived on the same page for 90 days following the event.